View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
October 29, 2019

Wearable digital interventions make inroads for autistic children

Earlier this year, a randomised clinical trial successfully used the Superpower Glass intervention, deployed via Google Glass, to significantly improve the behaviour of autistic children ages six to 12 years.

By GlobalData Healthcare

Technologies related to augmented and virtual reality are now having a very real impact on the healthcare industry. There are myriad possibilities associated with this technology, including medical education, image-guided treatment, pre-operative surgical planning, physician productivity, patient education, operating room design, assistance for the visually impaired, and new behavioural health treatment options for autism patients.

Free Whitepaper
img

Never Trust, Always Verify: Is Zero Trust the Next Big Thing in Cybersecurity?

Cyberattacks continue to rise every year and no sector seems to be immune. Hackers target sensitive information such as organizational, client, and financial data, as well as intellectual property (IP) and proprietary functions. As digital transformation becomes a top priority for many organizations, traditional perimeter-based security models are no longer sufficient to address the growing cybersecurity concerns. Against the backdrop, enterprises explore zero trust as it takes a micro-level approach to authenticate and approve access at every point within a network. Reasons to read: The cybersecurity landscape is swiftly changing, and businesses need more awareness to meet the evolving change. The report highlights the current state of play and the future potential of the zero trust approach in cybersecurity to protect critical digital infrastructure of enterprises across sectors such as financial services, healthcare, telecom, and transportation, among others. Read our report and gather insights on the following topics:
  • Traditional vs zero trust protection
  • Key advantages and solution providers
  • Major industries and key players
  • Drivers and challenges
  • Top funded startups and Mergers & Acquisitions
  • Implementation challenges
by GlobalData
Enter your details here to receive your free Whitepaper.

Earlier this year, a randomised clinical trial successfully used the Superpower Glass intervention, deployed via Google Glass, to significantly improve the behaviour of autistic children ages six to 12 years, according to the Vineland Adaptive Behavior Scale socialisation subscale. 

This study compared the Superpower Glass intervention plus standard-of-care, applied behaviour analysis therapy to standard-of-care therapy alone and is the first randomised clinical trial to successfully improve the social behaviour of autistic children using a wearable digital intervention. 

The Superpower Glass intervention can be employed at home to augment standard-of-care therapy; it combines Google Glasses worn by the patient with an artificial intelligence platform and a smartphone app that help to detect facial expressions and reinforce social cues.

The software enabling the Superpower Glass intervention has now been licensed to Cognoa, which was recently granted an FDA breakthrough device designation for the intervention. 

Rising autism incidence rates, high costs associated with behavioural analysis and treatment, and a shortage of qualified specialists mean that children diagnosed with the disease cannot always access the recommended level of care. As such, wearable at-home digital solutions have the potential to fill a much-needed gap in the market.

Other players in this space include Brain Power, a US startup that aims to couple data collection and analytical tools with wearable technology, such as Google Glass, to generate neuro-assistive devices that can overcome some of the educational challenges associated with autism. 

Additionally, various healthcare institutes such as the Children’s Hospital of Philadelphia and Purdue University are currently exploring the use of digital medicine tools to improve care management and remote patient monitoring for pediatric autism patients.

Related Report

GlobalData (2018). Autism Global Clinical Trials Review, H2, 2018, GDHC5455CTIDB

Related Companies

Free Whitepaper
img

Never Trust, Always Verify: Is Zero Trust the Next Big Thing in Cybersecurity?

Cyberattacks continue to rise every year and no sector seems to be immune. Hackers target sensitive information such as organizational, client, and financial data, as well as intellectual property (IP) and proprietary functions. As digital transformation becomes a top priority for many organizations, traditional perimeter-based security models are no longer sufficient to address the growing cybersecurity concerns. Against the backdrop, enterprises explore zero trust as it takes a micro-level approach to authenticate and approve access at every point within a network. Reasons to read: The cybersecurity landscape is swiftly changing, and businesses need more awareness to meet the evolving change. The report highlights the current state of play and the future potential of the zero trust approach in cybersecurity to protect critical digital infrastructure of enterprises across sectors such as financial services, healthcare, telecom, and transportation, among others. Read our report and gather insights on the following topics:
  • Traditional vs zero trust protection
  • Key advantages and solution providers
  • Major industries and key players
  • Drivers and challenges
  • Top funded startups and Mergers & Acquisitions
  • Implementation challenges
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology